Amicus Therapeutics' low P/S ratio suggests investor worries...
Amicus Therapeutics' low P/S ratio suggests investor worries about weak revenue growth compared to the booming Biotech sector, potentially hindering significant share price gains soon.
Lacklustre Performance Is Driving Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Low P/S
免责声明:以上信息不代表Moomoo Technologies Inc.("MTI")的任何立场,不构成与MTI及其关联公司的任何投资建议。
更多信息
评论
登录发表评论